Commitment to ensuring the Clinical Trials Action Group recommendations are implemented in full as soon as possible.
A thriving and vibrant clinical trials program in every treatment centre, enhances medicine for everyone – patients, health professionals, researchers, students, government, health care funders, and industry. Red tape is reducing the attractiveness of Australia as a venue for clinical trials and threatens the future of clinical trials in Australia.
It is a great concern for the Leukaemia Foundation that as a consequence, Australian blood cancer patients are missing out on accessing trials and new therapies.
What we know
- Our patient surveys demonstrate one of the most effective ways
for people to access new targeted therapies not yet available on the PBS, is
through clinical trials.
- Although Australia is only a small part (1-2%) of the global pharmaceutical market (Medicines Australia Facts Book 3 p.54), it is attractive for clinical research because of its internationally recognised strengths - the high quality of medical practice and clinical research environment, and a good health system which is well integrated with health and medical research, education and training.
- A clinical trials survey (Clinical Trials Action Group Report (2011)Clinically competitive: Boosting the business of clinical trials in Australia) showed patient recruitment delays in 90% of industry sponsored trials in Australia indicated that more efficient and effective recruitment strategies are essential.
- Clinical trials are research activities involving humans so safety and ethical considerations make the governance of trials complex.
- In June 2010, a government report by the Clinical Trials
Action Group made six recommendations to the then Minister to improve clinical
trials in Australia. These were to:
- improve the timeliness of ethics and research governance review;
- provide for cost recovery of efficient clinical trials;
- ensure clinical trials can take advantage of the developing e-Health system; improve patient recruitment;
- facilitate better national coordination and greater collaboration across clinical trials networks; and
- progress key clinical trial issues.
- These reforms aimed to ensure patients receive high quality, better coordinated, and sustainable health care in the future.
- Efforts to implement all six recommendations need to be recharged.
The current status of the recommendations can be found here.
Election commitment sought
Enhance existing systems and capacity to establish a national clinical quality registry for blood cancers in the next term of Government.